Search

Displaying results 4371 - 4380 of 10000 in total
  1. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes. … IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia.

  2. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    [L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.

    Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents
  3. Drug

    Corticosterone

    go.drugbank.com/drugs/DB04652
    Investigational

    (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437) … An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.

    Categories: Hormones, Hormone Substitutes, and Hormone Antagonists
  4. Drug

    Reldesemtiv

    go.drugbank.com/drugs/DB15256
    Investigational

    Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).

    Synonyms: CK-2127107
  5. Drug

    Buntanetap

    go.drugbank.com/drugs/DB15317
    Investigational

    Buntanetap (previously known as Posiphen) is under investigation in clinical trial NCT02925650 (Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease).

  6. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    ankylosing spondylitis,[L40584] rheumatoid arthritis,[L40589] psoriatic arthritis,[L40594] graft-versus-host disease,[A245653,L40599] vitiligo,[L40609] ulcerative colitis,[L40614] alopecia areata,[L40624] and

  7. Drug

    Pizotifen

    go.drugbank.com/drugs/DB06153
    Approved

    Sandomigran is available in a number of countries but is not approved by the FDA nor EMA. … It exhibits weak anticholinergic, antihistamine, and antikinin actions in addition to sedative and appetite-stimulating properties [L2292].

  8. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983] … MF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase.

  9. Drug

    Rauwolfia serpentina root

    go.drugbank.com/drugs/DB09363
    Investigational

    Reserpine is derived from Rauwolfia serpentina, and was commonly used as an antihypertensive agent in the 1950s [L1621]. Rauwolfia serpentina is also commonly referred to as _Sarpaghanda_ [A32097]. … This product was approved prior to Jan 1, 1982, but since, has been discontinued due to its propensity for leading to depression [L1616, L1630].

    Categories: rauwolfia alkaloids, whole root and diuretics
  10. Drug

    Tenapanor

    go.drugbank.com/drugs/DB11761
    ApprovedInvestigational

    [A185492] As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class[A185489,A185492,A185495] and therefore exists as … [L8558] It was first designed and synthesized in 2012.

    Categories: Alimentary Tract and Metabolism